Editas Medicine, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 7, 2020 and accepted by EDGAR at Aug 7, 2020, 08:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $10.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $16.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $28.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $62.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$31.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$78.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$23.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$61.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | −$1.12 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$84.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $4.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $485.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $610.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $655.5m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $68.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $228.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $426.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-20-009821. Last ingested by Listed: Nov 10, 2026, 02:10 ET. Listed shows no prices and gives no investment advice.